June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Anti-angiogenic effects of DS-7080a an anti-ROBO4 monoclonal antibody, in a monkey model of LASER-induced choroidal neovascularization
Author Affiliations & Notes
  • Tatsuya Inoue
    Daiichi Sankyo Co., Ltd., Tokyo, Japan
    Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Yoshitaka Isumi
    Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Shinko Hayashi
    Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Keiichi Fusegawa
    Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Yasushi Yoshigae
    Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Toshiyuki Sato
    Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Footnotes
    Commercial Relationships   Tatsuya Inoue, Daiichi Sankyo (E); Yoshitaka Isumi, Daiichi Sankyo (E); Shinko Hayashi, Daiichi sankyo (E); Keiichi Fusegawa, Daiichi Sankyo (E); Yasushi Yoshigae, Daiichi Sankyo (E); Toshiyuki Sato, Daiichi Sankyo (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1961. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tatsuya Inoue, Yoshitaka Isumi, Shinko Hayashi, Keiichi Fusegawa, Yasushi Yoshigae, Toshiyuki Sato; Anti-angiogenic effects of DS-7080a an anti-ROBO4 monoclonal antibody, in a monkey model of LASER-induced choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1961.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the effects of DS-7080a, an anti-ROBO4 monoclonal antibody, in an animal model of angiogenesis-related eye disease.

Methods : Choroidal neovascularization (CNV) was induced in male cynomolgus monkeys by subjecting the eyes to LASER treatment. DS-7080a was injected intravitreally at doses of 0.055, 0.22, and 1.1 mg/eye to assess its anti-angiogenic efficts (N=6 eyes, each group). ROBO4 mRNA expression was assessed in the choroid from patients with wet-AMD by in situ hybridization. The pharmacokinetics of intravitreally injected DS-7080a was analyzed in rabbits and monkeys.

Results : Three weeks after LASER exposure, mean (SD) of the incidence of Grade 4 CNV leakage was 48.15 (46.97) % in control monkeys but 1.85 (4.53)% in monkeys which received 1.1 mg/eye of DS-7080a. DS-7080a decreased CNV leakage dose-dependently. ROBO4 mRNA was detected the choroid from wet-AMD patients, especially in small vessels extending toward the Bruch’s membrane. Pharmacokinetics analysis showed DS-7080a may persist in the retina upon intravitreal injection for more than a month at effective concentrations.

Conclusions : DS-7080a may represent a novel therapeutic option for angiogenesis-related eye diseases such as wet AMD.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×